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Abstract
Introduction: Almost 30% of patients with pancreatic cancer have locally advanced tumours in absence of distant
metastasis. Surgical resection is often contraindicated. The combination of gemcitabine with concurrent radiation therapy
is a promising new approach that is being investigated for treating patients' unresectable pancreatic cancer. This work
aims at assessing the efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate
for patients' locally advanced pancreatic cancer.
Patients and methods: From March 2006 to November 2007, 25 patients with locally advanced non metastatic
pancreatic cancer were treated by preoperative gemcitabine based chemo-radiotherapy. The radiation dose was 54 Gray
in 30 fractions over 6 weeks prescribed to the isocenter. Gemcitabine (300 mg/m2) was given through a 30 minute
intravenous infusion. This was done 30 minutes before the radiation sitting on a weekly basis throughout the
radiotherapy course.
Approximately 6 weeks after the completion of chemo radiation, an evaluation was performed regarding tumour
response and resectability as well as acute toxicity. Pancreaticoduodenectomy was performed for operable patients with
surgical reconstruction.
Results: Patients who achieved complete resection (CR) numbered 2 (8%), while those achieving partial resection (PR)
totalled 11 (44%); six of these patients were considered ro be operable. Thus Pancreaticoduodenectomy was performed
on 8 patients (2 with CR and 6 with PR) with surgical reconstruction. Patients who had a stable disease numbered 4
(16%), and those with progressive diseases included a group of eight (32%). The postoperative 30 day mortality occurred
only in one patient (12.5%). Acute toxicity of chemoradiation occurred in the form of grade I leucopoenia and
thrombocytopenia. Hepatic toxicity, nausea, and vomiting were found in 8 patients (32%), 10 patients (40%) and 4
patients (16%), respectively. The postoperative 30 day mortality occurred only in 1 patient. Also, minor biliary leakage
and leakage from gastrointestinal anaestomosis both occurred in a single patient. Out of the 8 patients who underwent
radical surgical resection, only one developed local recurrence and simultaneous liver metastasis during the follow up
period. The median survival of all patients was 12 months.
Conclusion:  Preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non
metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.
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Introduction
Almost 30% of patients with pancreatic cancer have
locally advanced tumours in absence of distant metastasis.
Because surgical resection is often contraindicated by vas-
cular invasion, this condition has a dismal prognosis [1].
Therefore the role of preoperative chemoradiation in
treatment of locally advanced non metastatic pancreatic
cancer was investigated to help increase the rate of tumour
resectability. Up to now, 5-flurouracil has been consid-
ered the standard agent for concurrent chemradiotherapy
[2]. The combination of gemcitabine with concurrent
radiation therapy is a promising new approach that is
being investigated for treating patients' unresectable pan-
creatic cancer [3]. The aim of this study was to asses
whether preoperative gemcitabine based chemo-radio-
therapy increases the resectability rate for patients with
locally advanced pancreatic adenocarcinoma without dis-
tant metastasis.
Patients and methods
The current prospective study included 25 patients with
locally advanced non metastatic pancreatic cancer and
was carried out at radiation oncology and surgical oncol-
ogy departments, South Egypt Cancer Institute, Assiut
University during the period from March 2006 to Novem-
ber 2007. Informed consent was given by every patient
who participated in this study, and the study was
approved by our ethical committee.
Inclusion criteria
The study included patients having pancreatic cancer with
the following eligibility criteria: patients less than 70 years
of age; patients with an ECOG performance status index
which is at most 2; patients with surgically unresectable
pancreatic carcinoma, or T4 disease (i.e. tumour encase-
ment of celiac or superior mesenteric arteries as seen by
CT scans and Doppler studies).
Work up
Every patient in the study was subject to a history checks,
physical examinations, laboratory investigations includ-
ing tumour markers (CEA and CA19-9), and radiological
studies (chest x-rays, abdominopelvic CT scans with con-
trast enhanced triple phase helicals, and Doppler studies).
For jaundiced patients, ERCP and stent were performed.
All patients were treated by preoperative gemcitabine
based chemo-radiotherapy.
• Radiotherapy (conformal radiotherapy): Each
patient lied in a supine position on the flat table of the
CT scan machine with radio-opaque markers in the
midline and both sides of the patient defining the ref-
erence isocenter. Multiple CT slices of 0.5 cm intervals
were taken through out the treatment volume. CT data
were then transferred to the computer planning sys-
tem. On each slice, a planning target volume was
defined and included the gross disease as seen by CT
scan. Two 0.5 cm safety margins were put in place to
account for microscopic extension and for set up
uncertainties. A 3D plan was then created taking into
consideration the ICRU 50 recommendations and
dosimetric limits for hepatic, renal and spinal cord
toxicity criteria (i.e. the mean doses to the whole liver
and to each kidney did not exceed 30 Gray, and 18
Gray respectively). The maximum dose to any point
the in spinal cord did not exceed 45 Gray. All patients
were treated by a photon beam of 15 MV in energy
generated from a linear accelerator. The dose was 54
Gray in 30 fractions over 6 weeks (180 centi-Grays per
fraction) prescribed to the isocenter.
￿ Chemotherapy: Each patient was given gemcitabine
(300 mg/m2) through a 30 minute intravenous infu-
sion. This occurred 30 minutes before the radiation
sitting on a weekly basis throughout radiotherapy
course.
Evaluation
Approximately 6 weeks after the completion of chemo
radiation, an evaluation was performed by physical exam-
inations, tumour markers, and radiological studies,
including abdominopelvic CT scans and Doppler studies.
Each patient was evaluated regarding tumour response
and resectability as well as acute toxicity according to the
WHO common toxicity criteria, 1998.
Surgery
At the time of surgery, abdominal laparoscopy was done
for the 2 patients with CR and the patients with PR and no
encasement of SM vessels to find peritoneal and or
mesenteric metastases undetected by imaging. Thus, these
patients were excluded from surgical exploration. At time
of exploration, bilateral subcostal incisions were done for
operable patients who underwent a pancreaticoduo-
denectomy (Whipple resection). Surgical reconstruction
was done by pancreatic anastomosis; six patients under-
went a pancreaticogastrostomy, where antrectomy of the
stomach was done to leave a large residual stomach for
insertion of the pancreatic stump into the gastric lumen.
The pancreatic remnant was freed from the retroperito-
neal space to provide about 3 cm of opening. A corre-
sponding transverse opening was made on the posterior
gastric wall. Only two patients underwent classical pan-
creaticojejunostomy.
Results
Patients' characteristics
The age of our patients ranged between 40 and 68 years
with a median of 46 years. Males constituted 60% ofInternational Archives of Medicine 2009, 2:7 http://www.intarchmed.com/content/2/1/7
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patients with a male to female ratio of 1.5 to 1. According
to the ECOG performance status, 5 (20%) patients had a
score of 0, 15 (60%) had score of 1 and 5 (20%) had score
of 2. The main presenting symptom was abdominal pain
(20 out of 25 patients; 80%) while jaundice, GIT symp-
toms, fatigue and weight loss were reported in 60%, 40%,
32% and 28% of patients, respectively. Regarding TNM
staging, most of our patients (22 out of 25 patients, 88%)
showed a tumour size of ≥ 2 cm and only 10 patients
(40%) showed radiological evidence of regional LN
enlargement, table 1.
Response after chemoradiation
Evaluation of response after chemoradiotherapy showed
that only 2 out of 25 patients achieved CR (8%) while
those achieving PR numbered 11 out of 25 (44%). Three
of these patients still showed encasement of SMVs, and 2
patients out of the remaining 8 patients with no SMV
encasement showed laparoscopic evidence of peritoneal
and/or mesenteric seedling and thus were excluded from
exploration. The other 6 patients with PR as well as the 2
patients with CR were evaluated and underwent radical
surgery. Patients who had a stable disease totalled 4 out of
25 (16%), and those with progressive diseases numbered
8 out of 25 (32%), table 2.
Tumour respectability
Only 8 patients (32%) were considered respectable
(underwent Whipple's operation) and included those
who achieved CR in response to preoperative chemoradi-
ation (2 patients) and those who achieved PR with no
radiological evidence of SMV encasement and with no
laparoscopic evidence of peritoneal and/or mesenteric
seedling (6 patients), table 2 and figure 1. Prognostic fac-
tors which might predict tumor resectability were studied,
table 3. Tumour size was the only factor which signifi-
cantly affected pancreatic cancer resectability (P = 0.024).
Treatment related toxicities and postoperative morbidity 
and mortality
Toxicities of preoperative chemoradiation were mainly
haematological, where grade 1 leucopoenia and thrombo-
cytopenia were found in 8 out of 25 patients (32%), grade
1 hepatic toxicity was discovered in 10 patients (40%),
and grade 1 nausea and vomiting occurred in 4 patients
(16%). The postoperative 30 day mortality occurred only
in one patient (12.5%) due to a reactionary haemorrhage
from the portal vein. The postoperative morbidity
occurred in the form of minor biliary leakage (1 patient,
12.5%) and leakage from gastrointestinal anastomosis (1
patient, 12.5%) that healed conservatively. Delayed gas-
tric emptying occurred in 3 patients (37.5%).
Disease relapse and survival, figure 2
Out of 8 patients who underwent radical surgical resec-
tion, one patient died one month after surgery, and one
patient (12.5%) developed local recurrence and simulta-
neous liver metastasis during the follow up period and
eventually died after a follow up of 14 months. The
median survivals were 12 months and 8 months for all
patients and unresected patients, respectively. The survival
curves for resected and unresected patients are signifi-
cantly different and favour resected cases, with the 1 year
Table 1: Patients' characteristics
Variable No %
1- Age at diagnosis:
• 40–49 years 14 56
￿ 50–69 years 11 44
2- Sex:
￿ Male 15 60
￿ Female 10 40
3- Performance status (ECOG system):
￿ Score 0 5 20
￿ Score 1 15 60
￿ Score 2 5 20
4- Presenting symptoms:
￿ pain 20 80
￿ Jaundice 12 60
￿ GIT symptoms 10 40
￿ Fatigue 8 32
￿ Weight loss 7 28
5- Tumour size:
￿ <2 cm 3 12
￿ ≥ 2 cm 22 88
6- LN status:
￿ LN negative 15 60
￿ LN positive 10 40
Total 25 100
Table 2: Response to chemoradiation and tumour respectability
Variable No %
CR 2 (Resectable) 8
PR 11 (6 patients of them were resectable) 44
SD 4 16
PD 8 32
Total 25 100International Archives of Medicine 2009, 2:7 http://www.intarchmed.com/content/2/1/7
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survival rates being 87.5% and 22.4% for resected and
unresected cases, respectively (P = 0.02).
Discussion
Improved resectability is a major theoretical benefit of
preoperative chemoradiation for pancreatic cancer [4].
The combination of gemcitabine with concurrent radia-
tion therapy is a promising new approach that is being
used in patients with unresectable pancreatic cancer [3].
The age and sex distribution in the present study showed
that the median age of patients was 46 years with male to
female ratio of 1.5:1. These data are matched with Egyp-
tian figures [5] and also matched with western ones [6].
Pancreatic tumours with the greatest dimension (≥ 2 cm)
were present in most of cases (22 patients; 88%). This fig-
ure is higher than the one reported by Maheshwari and
Moser [1] who found that only 30% of patients with pan-
creatic cancer have large, locally advanced tumors and
non metastatic disease. This difference may be partly due
to a lack of routine check up procedures in developing
countries (including Egypt) and partly due to the delay of
attendance of most cases to the cancer institute.
About two thirds of patients in this study (17 out of 25;
68%) showed radiographic evidence of response to pre-
operative chemoradiation: Two of them showed CR, 11
showed PR, and 4 had a stable disease. These figures are
comparable with those found by White et al. [4] where
64% of patients had decreased or stable primary tumour
sizes after neoadjuvant therapy. The remission rate (CR &
PR) in the present study was 52% (13 out of 25 patients)
which was lower than that reported by Wilkowshi et al.
[2] who observed a 69% remission rate. This higher remis-
sion rate may be due to the addition of weekly cisplatin in
the chemotherapy given in the reported study. On the
other hand, our figures are higher than those reported by
Smeenk et al. [7] who stated that only 42% (16 out of 38)
of patients showed radiographic evidence of response
(26% PR & 16% SD). This difference may result from the
Treatment profile of patients with partial response Figure 1
Treatment profile of patients with partial response.
Table 3: Factors which might predict tumor resectability:
Resected cases Unresected cases
Variable No % No % P value
1-Age at diagnosis:
￿ 40–49 years 5 20 9 36 P > 0.05*
￿ 50–59 years 3 12 8 32
2-Sex:
￿ Male 5 20 10 40 P > 0.05*
￿ Female 3 12 7 28
3-Performance status:
￿ Score 0 3 12 2 8
￿ Score 1 4 16 11 44 P > 0.05*
￿ Score 2 1 4 4 16
4-Tumour size:
￿ <2 cm 3 12 0 0 P = 0.024**
￿ ≥ 2 cm 5 20 17 68
5-LN status:
￿ LN negative 5 20 10 40 P > 0.05*
￿ LN positive 3 12 7 28
￿ *Insignificant difference p > 0.05
￿ ** Significant difference p < 0.05International Archives of Medicine 2009, 2:7 http://www.intarchmed.com/content/2/1/7
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use of fluorouracil and not gemcitabine based chemoradi-
ation in the reported series in constrast to our study,
where gemcitabine based chemoradiotherapy was used.
The present study showed that 8 out of 25 patients (32%)
with locally advanced pancreatic cancer were surgically
resectable (2 patients of CR and 6 of PR with no radio-
graphic evidence of SMV encasement and no laparoscopic
evidence of peritoneal or mesenteric implantation). This
figure is comparable to that reported by Hoffman et al.
[8] and Wilkowshi et al. [2] who found that the resecta-
bility rates were 33% and 30%, respectively. However, our
figure is slightly lower than that reported by Brunner et al.
[9] where 37% (10 out of 37) of patients were considered
resectable. This slight difference may be due to the use of
different chemotherapy regimen (mitomycin C in addi-
tion to fluorouracil) concurrently with radiotherapy in the
reported study. Among factors which might predict tumor
resectability, tumor size was the only significant one. This
is in agreement with Reber [10] who stated that small
pancreatic tumors (<2 cm diameter) are more likely be
resectable than larger ones.
Regarding the toxicity to preoperative chemoradiation,
the incidences of grade I haematological toxicity (32%)
and grade 1 nausea and vomiting (16%) in our series were
Table 4: Results of Fung et al., 2003, meta-analysis.
No of trials regimens No of patients Average median an survival(months) Hazard ratio p-value
9 Best supportive care vs.
5-FU based combinations
434
262
3.87
6.38
0.53 <0.0001
7 5-FU/other agent alone vs.
5-FU based combination
428
414
5.23
4.98
0.88 0.1
3 5-FU based combination vs.
5-FU based combination
121
121
3.75
4.38
0.85 0.25
1 5-FU vs.
Gemcitabine
63
63
4.41
5.65
0.56 <0.005
2 Miscellaneous new agent vs.
Gemcitabine
241
242
3.70
6.08
0.61 <0.0001
7 Gemcitabine vs.
Gemcitabine based combination
758
745
6.62
6.98
0.92 0.15
Overall survival curves in both resected and unresected cases Figure 2
Overall survival curves in both resected and unresected cases.International Archives of Medicine 2009, 2:7 http://www.intarchmed.com/content/2/1/7
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lower than those reported by Bruner et al. [9] where grade
3 haematological toxicity was 30% and grade 3 nausea
and vomiting was 20%. The higher reported toxicity may
have occurred from the use of different chemotherapy reg-
imen which consisted of 5-flurouracil and mitomycin
concurrently with radiotherapy. In contrast to our study,
most of the reported trials using gemcitabine based chem-
oradiotherapy showed higher toxicity profiles, where
grade 3 hematological and nonhematological toxicities
were detected in 36% and 5% of patients, respectively
[11]. This could be explained by the use of gemcitabine
doses of 1000 mg/m2 given on days 1, 8 and 15 every 4
weeks in the reported series.
The incidence of disease relapse in this study (12.5%) was
similar to that found by the Lee Moffitt cancer centre
(12.5%) [12]. Two randomised trials evaluated chemora-
diation alone with radiation therapy and found that the
mean survival time was significantly increased from 6.3
months to 10.4 months when 5-FU was added to radio-
therapy (p < 0.05). In addition, the median survival time
was increased from 5.6 months to 8 months [13,14]. The
median survival among our patients was 12 months,
which was higher than that reported with radiotherapy
with concurrent 5-FU. This is consistent with the results of
a randomised trial conducted by Li et al. [15], who com-
pared radiotherapy with concurrent gemcitabine (18
patients) based on the same radiation therapy regimen
with 5-FU (16 patients). They found a statistically signifi-
cant median survival advantage in favour of the gemcitab-
ine group (14.5 versus 6.7 months; p < 0.027).
Our results are confirmed by a meta-analysis examining
the data from 29 randomised trials (including 3458
patients), and they support the notion that 5-FU based
chemotherapy regimens show better survival outcomes
over the best supportive care (<0.0001), and that gemcit-
abine based chemotherapy regimens show better survival
outcomes over 5-FU based regimens (<0.005) [16],
table 4.
The median survival in the current study is comparable to
that of the most reported series [10,17,18] which reported
median survivals of 11 months, 13 months, and 15.4
months, respectively. In the present study, the resected
cases showed significantly higher survival rates than that
of the unresected cases, where the 1 year survival rates
were 87.5% and 22.4% for resected and unresected cases,
respectively (P value; 0.02 and Hazard Ratio; 0.26 with
95% CI; 0.08 to 0.82). These figures are comparable to the
reported series where the 1 year survival rates were 87.5%
in the resected cases [19].
Conclusion
Although overall survival remains poor, treatment with
preoperative gemcitabine based chemoradiation might
benefit patients with locally advanced non metastatic
pancreatic cancer by helping to increase resectability with-
out significant acute toxicity.
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